Mitchell L. Shiffman
Editor

2012

Advances in Treatment, Promise
for the Future

I first began caring for patients with chronic hepatitis C virus (HCV) and participating in clinical trials to treat this virus in 1990. I distinctly remember enrolling my first patients with non-A, non-B hepatitis into a clinical trial in which they received either standard interferon alfa-2 a 1, 3, or 5 million IU or a placebo injection three times weekly.